Skip to main content

Advertisement

SpringerLink
Log in

Immune-mediated inflammation across disease boundaries: breaking down research silos

  • Comment
  • Published:

From Nature Immunology

View current issue Submit your manuscript

If new treatments for immune-mediated inflammatory diseases (IMIDs) are to emerge, then a radical new approach that moves the field from one that is based on clinical signs and symptoms to one that is based on immunological and molecular mechanisms is urgently needed. This requires a new way of thinking: that IMIDs should be approached as having shared common pathogenic cells and pathways, and that therapies should be targeted at these cells and processes rather than clinical features.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: Commonalities in autoimmune diseases.
Fig. 2: The need for a mechanistic marker to explore shared versus specific pathways in IMIDs.

References

  1. Robinson, D. Jr et al. Curr. Med. Res. Op. 22, 989–1000 (2006).

    Article  Google Scholar 

  2. Krishna, M. T. et al. Eur. Respir. J. 54, 1900476 (2019).

    Article  Google Scholar 

  3. Kuek, A., Hazleman, B. L. & Ostör, A. J. Postgrad. Med. J. 83, 251–260 (2007).

    Article  CAS  Google Scholar 

  4. Dinse, G. E. et al. Arthrit. Rheumatol. 72, 1026–1035 (2020).

    Article  CAS  Google Scholar 

  5. Tracey, D. et al. Pharmacol. Ther. 117, 244–279 (2008).

    Article  CAS  Google Scholar 

  6. Wijbrandts, C. A. & Tak, P. P. Mayo Clin. Proc. 92, 1129–1143 (2017).

    Article  CAS  Google Scholar 

  7. Corcoran, S. E., Halai, R. & Cooper, M. A. Pharmacol. Rev. 73, 968–1000 (2021).

    Article  CAS  Google Scholar 

  8. Decout, A., Katz, J. D., Venkatraman, S. & Ablasser, A. Nat. Rev Immunol. 21, 548–569 (2021).

    Article  CAS  Google Scholar 

  9. Buckley, C. D. Nat. Rev. Immunol. 13, 59–66 (2013).

    Article  CAS  Google Scholar 

  10. Cárdenas-Roldán, J., Rojas-Villarraga, A. & Anaya, J.-M. BMC Med. 11, 73 (2013).

    Article  Google Scholar 

  11. Zenewicz, L. A., Abraham, C., Flavell, R. A. & Cho, J. H. Cell 140, 791–797 (2010).

    Article  CAS  Google Scholar 

  12. Okada, Y. et al. Nature 506, 376–381 (2014).

    Article  CAS  Google Scholar 

  13. David, T., Ling, S. F. & Barton, A. Clin. Exp. Immunol. 193, 3–12 (2018).

    Article  CAS  Google Scholar 

  14. Shooshtari, P., Huang, H. & Cotsapas, C. Am. J. Human. Gen. 101, 75–86 (2017).

    Article  CAS  Google Scholar 

  15. Shen, N. et al. Nat. Rev. Rheumatol. 8, 701–709 (2012).

    Article  CAS  Google Scholar 

  16. Worthington, J. & Silman, A. Clin. Exp. Immunol. 101, 390–392 (1995).

    Article  CAS  Google Scholar 

  17. Tough, D. F., Tak, P. P., Tarakhovsky, A. & Prinjha, R. K. Nat. Rev. Drug Discov. 15, 835–853 (2016).

    Article  CAS  Google Scholar 

  18. Sims, E. K. et al. Sci. Transl. Med. 13, eabc8980 (2021).

    Article  CAS  Google Scholar 

  19. Gerlag, D. M. et al. Ann. Rheum. Dis. 78, 179–185 (2019).

    Article  CAS  Google Scholar 

  20. Jumper, J. et al. Nature 596, 583–589 (2021).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK

    Christopher D. Buckley

  2. The Lorna and Yuti Chernajovsky Biomedical Research Foundation, Whitstable, UK

    Lorna Chernajovsky, Yuti Chernajovsky & Paul P. Tak

  3. Queen Mary University of London, London, UK

    Yuti Chernajovsky

  4. Immunology Research, GSK, Stevenage, UK

    Louise K. Modis

  5. School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland

    Luke A. O’Neill

  6. British Society for Immunology, London, UK

    Doug Brown

  7. Juvenile Diabetes Research Foundation, London, UK

    Rachel Connor

  8. Multiple Sclerosis Society, London, UK

    David Coutts

  9. Versus Arthritis, Chesterfield, UK

    Elizabeth A. Waterman

  10. University of Cambridge, Cambridge, UK

    Paul P. Tak

  11. Candel Therapeutics, Needham, Massachusetts, USA

    Paul P. Tak

  12. Multimorbidity Steering Group, Strategic Priorities Fund, Swindon, UK

    Paul P. Tak

Authors
  1. Christopher D. Buckley
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lorna Chernajovsky
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yuti Chernajovsky
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Louise K. Modis
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Luke A. O’Neill
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Doug Brown
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Rachel Connor
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. David Coutts
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Elizabeth A. Waterman
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Paul P. Tak
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yuti Chernajovsky.

Ethics declarations

Competing interests

C.D.B. is a founder of Mestag with founding equity (https://mestagtherapeutics.com). L.K.M. is an employee and has shares in GSK. All other authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Buckley, C.D., Chernajovsky, L., Chernajovsky, Y. et al. Immune-mediated inflammation across disease boundaries: breaking down research silos. Nat Immunol 22, 1344–1348 (2021). https://doi.org/10.1038/s41590-021-01044-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41590-021-01044-7

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation